ESR1 and breast cancer: Significant differences in expression of ZnT5, ZnT6, ZnT8, and ZnT9, between basal-estrogen receptor negative (ER-) and luminal-ER positive (ER+) subtypes of breast cancer were demonstrated [103], though how they affect cellular signaling or breast cancer progression remains unclear (Figure 2).